Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA3 | P07451 | 2/20 | 0.36 |
| ▸ | CA6 | P23280 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28961806 | 0.86 | LPL (0.47) | LPLLIPGCA9CA3CA6 | |
| SCHEMBL31114767 | 0.86 | LPL (0.47) | LPLLIPGCA9CA3CA6 | |
| SCHEMBL14274295 | 0.81 | LPL (0.50) | LPLLIPGCA9CA3CA6 | |
| SCHEMBL772615 | 0.80 | LPL (0.49) | LPLLIPGCA9CA3CA6 | |
| SCHEMBL16472112 | 0.80 | LPL (0.49) | LPLLIPGCXCR2IDO1TDO2 | |
| SCHEMBL1753525 | 0.80 | TRPA1 (0.43) | LPLLIPGCA9CA3CA6 | |
| SCHEMBL29395754 | 0.80 | LPL (0.49) | LPLLIPGCA9CA3CA6 | |
| SCHEMBL2821738 | 0.79 | CA1 (0.37) | LPLLIPGCA9CA3CA6 | |
| SCHEMBL2101542 | 0.79 | HSD17B10 (0.41) | LPLLIPGIDO1CA1CA2 | |
| SCHEMBL16426112 | 0.79 | ALOX15 (0.41) | LPLLIPGCA9CA3CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117730081-A | Substituted spirocyclic derivatives | 詹森药业有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2024046221-A1 | EGFR INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-03-07 | — | — | WO | disclosed |
| WO-2022237627-A1 | SUBSTITUTED SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| EP-3898621-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113227087-A | Macrocyclic compounds and their use in the treatment of disease | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020128925-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-3334741-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017025913-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-16 | — | — | WO | disclosed |
| EP-3107917-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015126376-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| US-20060264435-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| EP-1611091-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089885-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | LPL 4247/4885LIPG 4502/4885CA9 1021/4885 |
| US-20110166117-A1 | Novel Compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | LPL 1943/4885LIPG 1716/4885CA9 484/4885 |
| US-20060264435-A1 | Novel compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | LPL 1943/4885LIPG 1716/4885CA9 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.